David K Kyle

US Patent:

7396548, Jul 8, 2008

Filed:

Mar 19, 2003

Appl. No.:

10/508156

Inventors:

David J. Kyle - Columbia MD, US

Assignee:

Advanced BioNutrition Corporation - Columbia MD

International Classification:

A23K 1/18
A23K 1/17

US Classification:

426 2, 426805, 424442

Abstract:

An animal feed with a high level of arachidonic acid is produced from microalgae, and fed to aquatic animals grown in aquaculture. The arachidonic acid-rich microalgae are fed directly to the aquatic animals, or processed to produce an oil that can be used as a human nutritive supplement. The arachidonic acid-rich microalgae can be combined with long chain omega-3 fatty acids to provide a source of nutrition for humans and animals. The animal feed and nutritional supplements are free of animal byproducts.

US Patent:

7939710, May 10, 2011

Filed:

Apr 23, 2001

Appl. No.:

09/839536

Inventors:

Kirk Emil Apt - Columbia MD, US
F. C. Thomas Allnutt - Port Deposit MD, US
David J. Kyle - Catonsville MD, US
James Casey Lippmeier - Washington DC, US

Assignee:

Martek Biosciences Corporation - Columbia MD

International Classification:

C12N 15/82

US Classification:

800278, 800288, 800290

Abstract:

Most microalgae are obligate photoautotrophs and their growth is strictly dependent on the generation of photosynthetically-derived energy. In this study it is shown that the microalga can be engineered to import glucose and grow in the dark through the introduction of genes encoding glucose transporters. Both the human and glucose transporters facilitated the uptake of glucose by , allowing the cells to metabolize exogenous organic carbon and thrive, independent of light. This is the first successful trophic conversion of an obligate photoautotroph through metabolic engineering, and it demonstrates that methods of cell nourishment can be fundamentally altered with the introduction of a single gene. Since strains transformed with the glucose transport genes are able to grow non-photosynthetically, they can be exploited for the analysis of photosynthetic processes through mutant generation and characterization. Finally, this work also represents critical progress toward large-scale commercial exploitation of obligate phototrophic algae through the use of microbial fermentation technology, eliminating significant limitations resulting from light-dependent growth.

US Patent:

8008061, Aug 30, 2011

Filed:

Aug 21, 2007

Appl. No.:

11/842898

Inventors:

Kirk Emil Apt - Columbia MD, US
F. C. Thomas Allnutt - Port Deposit MD, US
David J. Kyle - Catonsville MD, US
James Casy Lippmeier - Washington DC, US

Assignee:

Martek Biosciences Corporation - Columbia MD

International Classification:

C12N 1/12

US Classification:

4352571, 4352572, 435946, 800278

Abstract:

Most microalgae are obligate photoautotrophs and their growth is strictly dependent on the generation of photosynthetically-derived energy. In this study it is shown that the microalga can be engineered to import glucose and grow in the dark through the introduction of genes encoding glucose transporters. Both the human and glucose transporters facilitated the uptake of glucose by , allowing the cells to metabolize exogenous organic carbon and thrive, independent of light. This is the first successful trophic conversion of an obligate photoautotroph through metabolic engineering, and it demonstrates that methods of cell nourishment can be fundamentally altered with the introduction of a single gene. Since strains transformed with the glucose transport genes are able to grow non-photosynthetically, they can be exploited for the analysis of photosynthetic processes through mutant generation and characterization. Finally, this work also represents critical progress toward large-scale commercial exploitation of obligate phototrophic algae through the use of microbial fermentation technology, eliminating significant limitations resulting from light-dependent growth.

US Patent:

8198067, Jun 12, 2012

Filed:

Jun 9, 2006

Appl. No.:

11/449829

Inventors:

David J. Kyle - Catonsville MD, US

Assignee:

Advanced Bionutrtion Corporation - Columbia MD

International Classification:

C12N 1/14
A61K 38/00
A23K 1/17

US Classification:

4352572, 4352571, 514 22, 514 23, 514 24, 424439, 424442

Abstract:

A microbial biomass, made from algae, bacteria, fungi, yeast, or combinations thereof, provides a feed for animals raised either in agriculture or aquaculture. A feed additive, and a therapeutic composition can also be made from a microbial biomass of algae, bacteria, fungi, yeast, or combinations thereof. The feed, feed additive, and therapeutic composition can comprise one or more proteins, peptides, antibodies, antibody fragments, or a combination thereof, wherein said proteins, peptides, antibodies, antibody fragments, or a combination thereof are non-native to the microbes of the biomass. The biomass can have therapeutic, bioactive, nutritional, and/or immunogenic properties.

US Patent:

20040047881, Mar 11, 2004

Filed:

Sep 5, 2003

Appl. No.:

10/654985

Inventors:

David Kyle - Catonsville MD, US

Assignee:

Advanced BioNutrition Corp.

International Classification:

A61K039/395
A61K035/80
C12N001/12

US Classification:

424/195170, 424/130100, 435/257200

Abstract:

A microbial biomass, made from algae, bacteria, fungi, yeast, or combinations thereof, provides a feed for animals raised either in agriculture or aquaculture. A feed additive, and a therapeutic composition can also be made from a microbial biomass of algae, bacteria, fungi, yeast, or combinations thereof. The feed, feed additive, and therapeutic composition can comprise one or more proteins, peptides, antibodies, antibody fragments, or a combination thereof, wherein said proteins, peptides, antibodies, antibody fragments, or a combination thereof are non-native to the microbes of the biomass. The biomass can have therapeutic, bioactive, nutritional, and/or immunogenic properties.

US Patent:

20040081638, Apr 29, 2004

Filed:

Oct 14, 2003

Appl. No.:

10/683361

Inventors:

David Kyle - Catonsville MD, US

International Classification:

A61K048/00
A23K001/165
A23K001/17

US Classification:

424/093200, 424/442000

Abstract:

An animal feed is provided with a macroalgal, plant, or animal, e.g., insect or crustacean, biomass with one or more non-native peptides, proteins, antibodies, therapeutics, or a combination thereof. The proteins can be therapeutic, bioactive, proteins. A gene encoding a protein, antibody, therapeutic, or combination thereof, can be incorporated into a virus, which in turn, infects an organism that is a component of the feed. The virus can infect the macroalgal, plant, or animal feed component without incorporating viral genes into the macroalgal, plant, or animal feed component.

US Patent:

20050027004, Feb 3, 2005

Filed:

May 28, 2004

Appl. No.:

10/855488

Inventors:

David Kyle - Catonsville MD, US
Henry Linsert - Alexandria VA, US

International Classification:

A61K031/202
A61K031/225
C12P007/64

US Classification:

514560000, 435134000

Abstract:

A method of treating a neurological disorder comprises administering to a person affected from such a disorder a microbial oil comprising DHA, a microbial oil comprising ARA or a combination of DHA and ARA oils in an amount sufficient to elevate the levels of circulating DHA and/or ARA in the person's blood to at least normal levels.

US Patent:

20060121468, Jun 8, 2006

Filed:

Jun 25, 2003

Appl. No.:

10/519114

Inventors:

F. C. Allnutt - Glenwood MD, US
David Kyle - Catonsville MD, US

International Classification:

C12Q 1/70
C12Q 1/68

US Classification:

435006000, 435005000

Abstract:

The present invention relates to the display of antigenic or allergenic components along with a tissue-targeting component on viruses or virus-like particles. Capsid protein genes are recombinantly modified to contain the specified components then expressed within a host organism, such as yeasts, bacteria, or algae, and allowed to spontaneously form active virus particles or virus-like particles. The recombinant complexes (virus or virus-like particle) can then be purified or used in situ as a therapeutic tool for disease or allergy prevention. The expression of multivalent and multifunctional components to increase the immunogenicity of the recombinant complexes, especially on oral administration, is provided.